The use of psychopharmaceutical drugs - Should the serum concentration be monitored?;Bruk av psykofarmaka - Bør serumkonsentrasjonen kontrolleres?

Tidsskrift for den Norske Laegeforening

Volumn 124, Issue 18, 2004, Pages 2362-2364

  Andersen, Solveig ^a   Refsum, Helge ^a   Tanum, Lars ^b  

^a Psykofarmakologisk Avdeling   (Norway)

^b Avd for Forskning og Undervisning   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTISPOROZOAL AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PSYCHOTROPIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZUCLOPENTHIXOL;

CEREBROSPINAL FLUID LEVEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG INDICATION; DRUG METABOLISM; DRUG RESPONSE; DRUG USE; GENOTYPE; HUMAN; PATIENT MONITORING; SHORT SURVEY; STANDARD; ARTICLE; BLOOD; COST BENEFIT ANALYSIS; DRUG MONITORING; HEALTH CARE QUALITY; MENTAL DISEASE; PATIENT COMPLIANCE; REFERENCE VALUE;

COST-BENEFIT ANALYSIS; DRUG MONITORING; HUMANS; MENTAL DISORDERS; PATIENT COMPLIANCE; PSYCHOTROPIC DRUGS; QUALITY ASSURANCE, HEALTH CARE; REFERENCE VALUES;

EID: 5444227317     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (13)

1. Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants. Cost implications and relevance to clinical practice. Clin Pharmacokinet 1999; 37: 147-65.
2. Eilers R. Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness. Clin Pharmacokinet 1995; 29: 442-50.
3. Johansen PW, Bergan S, Rootwelt H et al. Individualisert farmakoterapi basert på P-450 (CYP)-genotyping. Tidsskr Nor Lægeforen 2002; 122: 2781-3.
4. Ulrich S, Schrödter I, Partscht G et al. Therapeutisches drug-monitoring von psychotropen Pharmaka. Psychopharmakotherapie 2000; 7: 2-14.
5. Mitchell PB. Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol 2000; 49: 303-12.
6. Perry PJ. Therapeutic drug monitoring of anti-psychotics. Psychopharmacol Bull 2001; 35: 19-29.
7. Wilson JF. Survey of reference ranges and clinical measurements for psychoactive drugs in serum. Ther Drug Monit 2003; 25: 243-7.
8. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998; 49: 196-201.
9. Demyttanare K, Enzlin P, Dewe W et al. Compliance with antidepressants in a primary care setting. Beyond lack of efficacy and adverse events. J Clin Psychiatry 2001; 62: 30-3.
10. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapin: the combined effect of age, gender, smoking and comedication. Ther Drug Monit 2003; 25: 46-53.
11. Loebstein R, Koren G. Clinical relevance of therapeutic drug monitoring during pregnancy. Ther Drug Monit 2002; 24: 15-22.
12. Nordeng H, Bergsholm YK, Bøhler E et al. Overgang av selektive serotoninreopptakshemmere til morsmelk. Tidsskr Nor Lægeforen 2001; 121: 199-203.
13. Rytter E, Håberg M. Forbruk av psykofarmaka ved psykiatriske sykehus i Norge 1991-2000. Tidsskr Nor Lægeforen 2003; 123: 768-71.